1036389-86-2

Basic information

• Product Name: 5-AMino-2-broMo-4-fluorobenzoic Acid Methyl Ester
• Synonyms: 5-AMino-2-broMo-4-fluorobenzoic Acid Methyl Ester
• CAS NO: 1036389-86-2
• Molecular Formula: C₈H₇BrFNO₂
• Molecular Weight: 248.0490832
• Product Categories: Aromatics, Miscellaneous Reagents
• Mol File: 1036389-86-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-AMino-2-broMo-4-fluorobenzoic Acid Methyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMino-2-broMo-4-fluorobenzoic Acid Methyl Ester(1036389-86-2)
• EPA Substance Registry System: 5-AMino-2-broMo-4-fluorobenzoic Acid Methyl Ester(1036389-86-2)

Safety Data

• Hazardous Substances Data: 1036389-86-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Amino-2-bromo-4-fluorobenzoic Acid Methyl Ester is used as a key intermediate in the synthesis of lactam amino acid derivatives with anti-coagulant activity. These derivatives have the potential to be developed into novel therapeutic agents for the prevention and treatment of blood clot-related disorders, such as deep vein thrombosis, pulmonary embolism, and stroke.
In the synthesis process, 5-Amino-2-bromo-4-fluorobenzoic Acid Methyl Ester serves as a building block for the formation of lactam rings, which are essential structural components of many bioactive compounds. The presence of the bromine and fluorine atoms in the molecule can also contribute to the modulation of the biological activity and selectivity of the resulting lactam amino acid derivatives.
Furthermore, the versatility of 5-Amino-2-bromo-4-fluorobenzoic Acid Methyl Ester allows for the development of a range of structurally diverse lactam amino acid derivatives with varying anti-coagulant properties. This can lead to the discovery of more effective and safer anti-coagulant drugs, addressing the unmet medical needs in the prevention and treatment of blood clot-related conditions.

Upstream product

• 85953-31-7 2-bromo-4-fluoro-5-nitrobenzoic acid methyl ester 
• 1006-41-3 2-bromo-4-fluorobenzoic acid 

Downstream Products

• 1036389-88-4 5-amino-2-cyano-4-fluorobenzoate methyl ester 
• 1036389-90-8 6-amino-5-fluoro-isoindolin-1-one 
• 1036389-92-0 C₁₈H₁₇FN₂O₅ 

Relevant articles and documents

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

ASK1 INHIBITOR COMPOUNDS AND USES THEREOF

Described herein are compounds, including pharmaceutically acceptable salts, solvates, metabolites, prodrugs thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors

Inhibitors of Factor VIIa (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the S1 binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the S1 pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this P1 binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.

Sulfo-imidazole-diketone and imidazole-diketone compound and applications thereof

The invention discloses a sulfo-imidazole-diketone and imidazole-diketone compound and applications thereof. The invention provides the formula (I) compound (please see the specification) or pharmaceutical salt, solvate, prodrug, stereoisomer, tautomer and metabolite thereof, wherein X, Y, Z, R1, R2, R3 and A are defined in the formula. The invention further provides a preparing method for the compound and applications of the compound serving as an androgen receptor antagonist to treating diseases related to an androgen receptor, such as prostatic cancer, prostatic hyperplasia, acne, feather-loss disorder, hair hyperplasia, breast cancer and poor male sexual function.

A kind of diaryl hydanto?n derivatives, its preparation method, pharmaceutical composition and application

Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treating androgen receptor related diseases.

BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention provides novel bicyclic lactams derivatives, and analogues thereof, of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, B, C, W, Y, Z1, Z2, Z3, Z4, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention relates generally to novel macrocycles of Formula (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1, Z2, Z3, Z4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.